1033P IMreal Cohort 2: Second interim analysis of efficacy and safety data in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) under real-world conditions

Abstract

Atezo (anti–PD-L1 antibody) is approved for treatment (tx) of pts with advanced NSCLC after prior chemotherapy. IMreal (NCT03782207) is a non-interventional, global, multi-center, multi-cohort prospective study evaluating the short- and long-term outcomes and safety of atezo in pts in the real-world setting. Here we report the second interim efficacy and safety data for Cohort 2.